questionsmedicales.fr
Thérapeutique
Traitement médicamenteux
Association de médicaments
Bithérapie antiplaquettaire
Bithérapie antiplaquettaire : Questions médicales fréquentes
Diagnostic
5
Thrombose
Antiplaquettaires
Fonction plaquettaire
Tests de laboratoire
Infarctus du myocarde
Accident vasculaire cérébral
Maladies cardiovasculaires
Événements thromboemboliques
Événements cardiovasculaires
Complications
Symptômes
5
Effets secondaires
Saignements
Réaction allergique
Éruption cutanée
Saignements
Douleurs thoraciques
Hémorragie interne
Selles noires
Prévention
5
Prévention
Événements thromboemboliques
Mode de vie
Alimentation saine
Pression artérielle
Complications cardiovasculaires
Recommandations médicales
Événements cardiovasculaires
Traitements
5
Durée de traitement
Événements cardiovasculaires
Ajustement de traitement
Effets indésirables
Prévention
Événements thromboemboliques
Suivi médical
Tests de laboratoire
Complications
5
Complications
Saignements majeurs
Saignement majeur
Consultation médicale
Âge avancé
Insuffisance rénale
Complications graves
Changements neurologiques
Facteurs de risque
5
Facteurs de risque
Hypertension
Âge
Maladies cardiovasculaires
Stress
Maladies cardiovasculaires
Hérédité
Maladies cardiovasculaires
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Bithérapie antiplaquettaire : Questions médicales les plus fréquentes",
"headline": "Bithérapie antiplaquettaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Bithérapie antiplaquettaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-14",
"dateModified": "2026-05-04",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Bithérapie antiplaquettaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Association de médicaments",
"url": "https://questionsmedicales.fr/mesh/D004359",
"about": {
"@type": "MedicalCondition",
"name": "Association de médicaments",
"code": {
"@type": "MedicalCode",
"code": "D004359",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.319.310"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Bithérapie antiplaquettaire",
"alternateName": "Dual Anti-Platelet Therapy",
"code": {
"@type": "MedicalCode",
"code": "D000080903",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Monica Verdoia",
"url": "https://questionsmedicales.fr/author/Monica%20Verdoia",
"affiliation": {
"@type": "Organization",
"name": "Division of Cardiology, Azienda Ospedaliera-Universitaria \"Maggiore della Carità\", Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy."
}
},
{
"@type": "Person",
"name": "Giuseppe De Luca",
"url": "https://questionsmedicales.fr/author/Giuseppe%20De%20Luca",
"affiliation": {
"@type": "Organization",
"name": "Division of Cardiology, Azienda Ospedaliera-Universitaria \"Maggiore della Carità\", Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy. giuseppe.deluca@maggioreosp.novara.it."
}
},
{
"@type": "Person",
"name": "Patrizia Pergolini",
"url": "https://questionsmedicales.fr/author/Patrizia%20Pergolini",
"affiliation": {
"@type": "Organization",
"name": "Clinical Chemistry, Azienda Ospedaliera-Universitaria \"Maggiore della Carità\", Eastern Piedmont University, Novara, Italy."
}
},
{
"@type": "Person",
"name": "Matteo Nardin",
"url": "https://questionsmedicales.fr/author/Matteo%20Nardin",
"affiliation": {
"@type": "Organization",
"name": "Division of Cardiology, Azienda Ospedaliera-Universitaria \"Maggiore della Carità\", Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Platelet Function, Platelet Size and Content of Reticulated Platelets: Interactions in Patients Receiving Dual Antiplatelet Therapy.",
"datePublished": "2024-10-16",
"url": "https://questionsmedicales.fr/article/39451230",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cells13201712"
}
},
{
"@type": "ScholarlyArticle",
"name": "Thrombus aspiration is associated with improved platelet inhibition rate following dual antiplatelet therapy in acute myocardial infarction patients.",
"datePublished": "2024-08-14",
"url": "https://questionsmedicales.fr/article/39143607",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s40001-024-02018-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cost-effectiveness of platelet function testing in dual antiplatelet therapy decision-making after intracranial aneurysm treatment with flow diversion.",
"datePublished": "2024-08-27",
"url": "https://questionsmedicales.fr/article/39190045",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10143-024-02668-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of Dual Antiplatelet Therapies for Minor, Nondisabling, Acute Ischemic Stroke: A Bayesian Network Meta-Analysis.",
"datePublished": "2024-05-01",
"url": "https://questionsmedicales.fr/article/38753327",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2024.11735"
}
},
{
"@type": "ScholarlyArticle",
"name": "Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome.",
"datePublished": "2024-07-22",
"url": "https://questionsmedicales.fr/article/39038086",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1161/CIRCULATIONAHA.124.069012"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Thérapeutique",
"item": "https://questionsmedicales.fr/mesh/D013812"
},
{
"@type": "ListItem",
"position": 3,
"name": "Traitement médicamenteux",
"item": "https://questionsmedicales.fr/mesh/D004358"
},
{
"@type": "ListItem",
"position": 4,
"name": "Association de médicaments",
"item": "https://questionsmedicales.fr/mesh/D004359"
},
{
"@type": "ListItem",
"position": 5,
"name": "Bithérapie antiplaquettaire",
"item": "https://questionsmedicales.fr/mesh/D000080903"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Bithérapie antiplaquettaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Bithérapie antiplaquettaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Bithérapie antiplaquettaire",
"description": "Comment diagnostiquer un besoin de bithérapie antiplaquettaire ?\nQuels tests sont utilisés pour évaluer la fonction plaquettaire ?\nQuand envisager une bithérapie antiplaquettaire ?\nQuels critères cliniques justifient cette thérapie ?\nComment évaluer l'efficacité de la bithérapie ?",
"url": "https://questionsmedicales.fr/mesh/D000080903#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Bithérapie antiplaquettaire",
"description": "Quels symptômes indiquent une thrombose ?\nQuels effets secondaires peuvent survenir ?\nComment reconnaître une réaction allergique ?\nQuels signes d'alerte nécessitent une consultation ?\nQuels symptômes peuvent indiquer une hémorragie interne ?",
"url": "https://questionsmedicales.fr/mesh/D000080903#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Bithérapie antiplaquettaire",
"description": "Comment prévenir les événements thromboemboliques ?\nQuels changements de mode de vie sont recommandés ?\nQuel rôle joue le contrôle de la pression artérielle ?\nComment le diabète influence-t-il la bithérapie ?\nPourquoi est-il important de suivre les recommandations médicales ?",
"url": "https://questionsmedicales.fr/mesh/D000080903#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Bithérapie antiplaquettaire",
"description": "Quels médicaments sont utilisés en bithérapie ?\nQuelle est la durée typique de la bithérapie ?\nComment ajuster le traitement en cas d'effets secondaires ?\nQuels sont les objectifs de la bithérapie ?\nComment surveiller l'efficacité du traitement ?",
"url": "https://questionsmedicales.fr/mesh/D000080903#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Bithérapie antiplaquettaire",
"description": "Quelles sont les complications possibles de la bithérapie ?\nComment gérer un saignement majeur ?\nQuels facteurs augmentent le risque de complications ?\nComment prévenir les complications liées à la bithérapie ?\nQuels signes indiquent une complication grave ?",
"url": "https://questionsmedicales.fr/mesh/D000080903#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Bithérapie antiplaquettaire",
"description": "Quels sont les principaux facteurs de risque cardiovasculaire ?\nComment l'âge influence-t-il le risque ?\nQuel impact a l'obésité sur la santé cardiovasculaire ?\nComment le stress affecte-t-il le risque cardiovasculaire ?\nQuel rôle joue l'hérédité dans le risque ?",
"url": "https://questionsmedicales.fr/mesh/D000080903#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un besoin de bithérapie antiplaquettaire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation des antécédents cardiovasculaires et des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la fonction plaquettaire ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme l'agrégation plaquettaire et le dosage de marqueurs spécifiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Quand envisager une bithérapie antiplaquettaire ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est envisagée après un infarctus du myocarde ou un AVC ischémique."
}
},
{
"@type": "Question",
"name": "Quels critères cliniques justifient cette thérapie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de maladies cardiovasculaires et les événements thromboemboliques sont des critères."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité de la bithérapie ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par la réduction des événements cardiovasculaires et des complications."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une thrombose ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur thoracique, essoufflement, ou gonflement des membres."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent des saignements, des ecchymoses et des troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent éruption cutanée, démangeaisons, ou gonflement du visage et de la gorge."
}
},
{
"@type": "Question",
"name": "Quels signes d'alerte nécessitent une consultation ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements inhabituels ou des douleurs thoraciques persistantes doivent être évalués."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une hémorragie interne ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs abdominales, des vomissements de sang ou des selles noires."
}
},
{
"@type": "Question",
"name": "Comment prévenir les événements thromboemboliques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La bithérapie, associée à des changements de mode de vie, aide à prévenir ces événements."
}
},
{
"@type": "Question",
"name": "Quels changements de mode de vie sont recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine, l'exercice régulier et l'arrêt du tabac sont recommandés."
}
},
{
"@type": "Question",
"name": "Quel rôle joue le contrôle de la pression artérielle ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un bon contrôle de la pression artérielle réduit le risque de complications cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Comment le diabète influence-t-il la bithérapie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diabète augmente le risque de thrombose, nécessitant souvent une bithérapie plus agressive."
}
},
{
"@type": "Question",
"name": "Pourquoi est-il important de suivre les recommandations médicales ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Suivre les recommandations réduit le risque d'événements cardiovasculaires et d'hémorragies."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés en bithérapie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les médicaments courants incluent l'aspirine et le clopidogrel ou le ticagrelor."
}
},
{
"@type": "Question",
"name": "Quelle est la durée typique de la bithérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée varie, mais elle est souvent recommandée pendant 6 à 12 mois après un événement cardiovasculaire."
}
},
{
"@type": "Question",
"name": "Comment ajuster le traitement en cas d'effets secondaires ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le médecin peut réduire la dose ou changer de médicament en cas d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Quels sont les objectifs de la bithérapie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'objectif est de prévenir les événements thromboemboliques et d'améliorer la survie."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suivis réguliers et des tests de laboratoire aident à évaluer l'efficacité du traitement."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la bithérapie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des saignements majeurs, des AVC hémorragiques et des troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Comment gérer un saignement majeur ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "En cas de saignement majeur, il faut consulter immédiatement un médecin et arrêter les médicaments."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, les antécédents de saignements et l'insuffisance rénale augmentent le risque."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées à la bithérapie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier et une évaluation des risques permettent de prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs abdominales sévères, des vomissements de sang ou des changements neurologiques sont alarmants."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque cardiovasculaire ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'hypertension, le diabète, le tabagisme et l'hyperlipidémie."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le risque de maladies cardiovasculaires augmente avec l'âge, nécessitant une vigilance accrue."
}
},
{
"@type": "Question",
"name": "Quel impact a l'obésité sur la santé cardiovasculaire ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité est un facteur de risque majeur pour les maladies cardiovasculaires et la thrombose."
}
},
{
"@type": "Question",
"name": "Comment le stress affecte-t-il le risque cardiovasculaire ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut augmenter le risque de maladies cardiovasculaires et d'événements thromboemboliques."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'hérédité dans le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux de maladies cardiovasculaires augmentent le risque individuel."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 04/05/2026
Contenu vérifié selon les dernières recommandations médicales
6 publications dans cette catégorie
5 publications dans cette catégorie
Affiliations :
Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della Carità", Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy.
Publications dans "Bithérapie antiplaquettaire" :
5 publications dans cette catégorie
Affiliations :
Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della Carità", Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy. giuseppe.deluca@maggioreosp.novara.it.
Publications dans "Bithérapie antiplaquettaire" :
4 publications dans cette catégorie
Affiliations :
Clinical Chemistry, Azienda Ospedaliera-Universitaria "Maggiore della Carità", Eastern Piedmont University, Novara, Italy.
Publications dans "Bithérapie antiplaquettaire" :
4 publications dans cette catégorie
Affiliations :
Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della Carità", Eastern Piedmont University, C.so Mazzini, 18, 28100, Novara, Italy.
Publications dans "Bithérapie antiplaquettaire" :
4 publications dans cette catégorie
Affiliations :
Clinical Chemistry, Azienda Ospedaliera-Universitaria "Maggiore della Carità", Eastern Piedmont University, Novara, Italy.
Publications dans "Bithérapie antiplaquettaire" :
4 publications dans cette catégorie
Affiliations :
Department of Cardiology, UMC St Radboud, Nijmegen, The Netherlands.
Publications dans "Bithérapie antiplaquettaire" :
3 publications dans cette catégorie
Affiliations :
Division of Cardiology, Azienda Ospedaliera-Universitaria "Maggiore della Carità", Eastern Piedmont University, Novara, Italy.
Publications dans "Bithérapie antiplaquettaire" :
2 publications dans cette catégorie
Affiliations :
3 Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria.
Medical Faculty, Sigmund Freud University, Vienna, Austria.
Publications dans "Bithérapie antiplaquettaire" :
2 publications dans cette catégorie
Affiliations :
University of New Mexico School of Medicine.
Publications dans "Bithérapie antiplaquettaire" :
2 publications dans cette catégorie
Affiliations :
Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.
Publications dans "Bithérapie antiplaquettaire" :
2 publications dans cette catégorie
Affiliations :
Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.
Publications dans "Bithérapie antiplaquettaire" :
2 publications dans cette catégorie
Affiliations :
Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.
Departmet of Cardiology, Maria Cecilia Hospital, GVM Care and Research, Cotignola, Italy.
Publications dans "Bithérapie antiplaquettaire" :
2 publications dans cette catégorie
Affiliations :
Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.
Publications dans "Bithérapie antiplaquettaire" :
2 publications dans cette catégorie
Affiliations :
Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.
Publications dans "Bithérapie antiplaquettaire" :
2 publications dans cette catégorie
Affiliations :
Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.
Publications dans "Bithérapie antiplaquettaire" :
2 publications dans cette catégorie
Affiliations :
Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.
Publications dans "Bithérapie antiplaquettaire" :
2 publications dans cette catégorie
Affiliations :
Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.
Publications dans "Bithérapie antiplaquettaire" :
2 publications dans cette catégorie
Affiliations :
Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.
Publications dans "Bithérapie antiplaquettaire" :
2 publications dans cette catégorie
Affiliations :
Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.
Publications dans "Bithérapie antiplaquettaire" :
Increased platelet activity is a risk factor of thrombotic events in cardiovascular patients. We studied the relationship between platelet function, platelet size, and the content of reticulated plate...
It is well-established that thrombus aspiration during primary percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI) indicates a higher thrombus burden and necess...
To investigate platelet reactivity after DAPT in AMI patients with thrombus aspiration performed during PCI....
In this retrospective study, we examined 269 consecutive AMI patients who underwent PCI and recorded their demographic, clinical and laboratory data. The platelet reactivity was measured with thromboe...
Ultimately, 208 patients were included in this study and divided into a Thrombus Aspiration group (N = 97) and a PCI Alone group (N = 111) based on whether thrombus aspiration was performed or not. Th...
In conclusion, clinicians should exercise heightened attention towards the bleeding risk among patients undergoing PCI concomitant with Thrombus Aspiration postoperatively....
Dual antiplatelet therapy (DAPT) use is the standard of practice after flow diversion (FD) for intracranial aneurysms (IAs). Yet, no consensus exists in the literature regarding the optimal regimen. C...
Dual antiplatelet therapy (DAPT) appears to be an effective treatment option for minor (nondisabling) acute ischemic stroke. This conclusion is based on trials that include both transient ischemic att...
To compare DAPT regimens specifically for minor stroke....
PubMed was searched for randomized clinical trials published up to November 4, 2023. Search terms strategy included TIA, transient ischemic attack, minor stroke, or moderate stroke, with the filter ra...
Trials testing DAPT within the first 24 hours of a minor stroke (defined as a National Institutes of Health Stroke Scale score ≤5) were included by consensus. Of 1508 studies screened, 6 (0.3%) initia...
The study was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines by multiple observers. Bayesian fixed-effect network meta-analysis was conducted. Sec...
Treatments were ranked using a probability measure called surface under the cumulative rank curve (SUCRA). The primary outcome was subsequent ischemic stroke at 90 days. Secondary outcomes included ma...
Five trials were included that described 28 148 patients, of whom 22 203 (78.9%) had a minor stroke. Of these, 13 995 (63.0%) were in DAPT groups and 8208 (37.0%) in aspirin (acetylsalicylic acid) gro...
These findings suggest that DAPT with aspirin and ticagrelor has higher probability of being the superior treatment among patients with minor stroke when presence of CYP2C19 loss-of-function alleles h...
For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) has been the only class I recommendation on DAPT in American and European guidelines, which has resul...
This study estimates the temporal risk variations of ischemic and bleeding events during dual antiplatelet therapy (DAPT) among patients stratified according to the Academic Research Consortium for Hi...
A total of 1264 ACS patients receiving either clopidogrel or prasugrel with aspirin were classified by ARC-HBR; HBR (n = 574) and non-HBR groups (n = 690). This study was designed as a multicenter obs...
Ischemic and bleeding events were observed in 9.4% and 7.4%, respectively, during an average observation period of 313 days. The HBR group had a higher incidence of both events than the non-HBR group ...
A 60-day period of DAPT is appropriate to balance the risks of adverse events after ACS, regardless of ARC-HBR criteria....
The recommended duration of dual anti-platelet therapy (DAPT) following acute coronary syndrome (ACS) for patients without atrial fibrillation varies from 1 month to 1 year depending on the balance of...
One hundred consecutive ACS patients treated with percutaneous coronary intervention discharged from Middlemore Hospital and without atrial fibrillation in the first quarter of 2023 were studied. ANZA...
All patients were planned for DAPT at discharge and 91% a PPI. Up to four out of five ACS patients could have been planned for shorter DAPT durations based on the ESC guideline recommendations. Over h...
There was a divergence between clinical practice and the recommendations of the 2020 ESC guidelines. We discuss these results in relation to the updated August 2023 ESC guidelines, which have reaffirm...
Despite growing evidence for the effectiveness of stent-assisted coil embolization (SAC) in treating acutely ruptured aneurysms, the safety of stent placement in acute phase remains controversial beca...
We retrospectively evaluated 203 enrolled patients with acutely ruptured aneurysms, categorizing them into two groups: SAC and coiling-only groups. Comparative analyses between the two groups regardin...
130 (64.0%) patients were treated using the coiling-only technique, whereas 73 (36.0%) underwent SAC. There was a trend to a higher complete obliteration rate (p = 0.061) and significantly lower recan...
SAC with periprocedural DAPT could be a safe and effective treatment strategy for acutely ruptured aneurysms. Moreover, it might have a protective effect on postprocedural cerebral infarction without ...
This comprehensive review delves into the evolving field of neurointervention for intracranial aneurysms, exploring the critical adjunct of Dual Antiplatelet Therapy (DAPT) to endovascular coiling, st...
: This article has been withdrawn: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal). This article has been withdrawn at the request of the ...